Compare Bristol-Myers Squibb Co (BMY) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Procter & Gamble Co — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Procter & Gamble Co trades at $146.19 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 2.9× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PG | |
|---|---|---|
Market Cap | $116.30B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $167.18 |
52-Week Low | $42.60 | $138.10 |
Enterprise Value | $152.24B | $365.64B |
Dividend Yield | 4.42% | 2.92% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Procter & Gamble (PG) trades at $148.37, up 0.9% with a neutral technical outlook. The company maintains strong fundamentals with $84.28B revenue and 19.16% net income margin, consistently beating earnings estimates. Recent dividend declaration of $1.09 and WNBA partnership highlight stable returns and brand expansion. Analyst consensus is bullish with 53.85% buy ratings and $161.71 price target, though premium valuation metrics suggest cautious optimism.
PG offers steady growth with reliable dividends but faces margin pressure from rising costs. The stock's premium valuation requires sustained earnings growth to justify upside. Near-term resistance at $150 presents a key level to watch, while support at $145 provides downside protection. Institutional activity remains mixed amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
